Psoriasis of the scalp, face, intertriginous areas, genitals, hands, feet, and nails is often underdiagnosed, and disease management can be challenging. Despite the small surface area commonly affected by psoriasis in these locations, patients have disproportionate levels of physical impairment and emotional distress. Limitations in current disease severity indices do not fully capture the impact of disease on a patient's quality of life, and, combined with limitations in current therapies, many patients do not receive proper or adequate care. In this review, we discuss the clinical manifestations of psoriasis in these less commonly diagnosed areas and its impact on patient quality of life. We also examine clinical studies evaluating the effectiveness of therapies on psoriasis in these regions. This article highlights the need to individualize treatment strategies for psoriasis based on the area of the body that is affected and the emerging role of biologic therapy in this regard.
| Scalp
Scalp involvement occurs in 45-56% of individuals with psoriasis (Merola, Li, et al., 2016) . It is typically among the first affected areas of the body, with the frequency of lesion formation increasing with disease duration. The diagnosis of scalp psoriasis can be delayed due to overlapping features with other papulosquamous disorders of the scalp, particularly seborrheic dermatitis (Treadwell, 2011) . Psoriasis lesions on the scalp are usually asymmetrical and sharply demarcated, and exhibit silvery-white scaling.
The symptoms of scalp psoriasis can result in decreased QoL by causing pain, itching, bleeding, feelings of embarrassment, and restricting clothing choices (Sampogna, Linder, et al., 2014) . QoL is more adversely affected in women than men, and individuals younger than 40 years are more adversely affected compared with patients 60 years or older (Sampogna, Linder, et al., 2014) .
Common treatment options for patients with scalp psoriasis include topical agents such as vitamin D analogs, corticosteroids, and coal tar. However, these agents are challenging to use on the scalp because hair makes application burdensome, and many patients find them cosmetically unacceptable (Menter et al., 2011) .
These issues can lead to nonadherence and dissatisfaction with treatment options.
In a recent systematic review of topical therapies for chronic plaque psoriasis of the scalp, vitamin D and corticosteroid combination therapy, and corticosteroid monotherapy were found to be more effective and safer than vitamin D monotherapy (Schlager et al., 2016) .
However, monotherapy with generic topical steroids may be acceptable for short-term therapy due to the slim efficacy benefit of vitamin D and corticosteroid combination therapy over steroid therapy alone.
Targeted phototherapy with an excimer laser can provide an effective alternative to topical therapy when used with a blower device that displaces hair (Menter et al., 2010) . (Table 1) (Bagel et al., 2012 (Bagel et al., , 2017 Langley et al., 2015; Moore et al., 2007; Paul et al., 2012; Reich et al., 2017; Rich et al., 2016; Thaci, Unnebrink, Sundaram, Sood, & Yamaguchi, 2015; Tyring et al., 2013) . Similarly, a recent retrospective cohort study demonstrated the efficacy of infliximab and ustekinumab in addition to etanercept and adalimumab (Fotiadou et al., 2016) . Most reports were post hoc analyses of moderate-to-severe plaque psoriasis trials (Langley et al., 2015; Reich et al., 2017; Rich et al., 2016; Thaci et al., 2015) . To date, only 1 prospective clinical trial was conducted specifically in patients with moderate-to-severe scalp psoriasis without a requirement to have body-surface-area involvement 10% (Bagel et al., 2017) . This placebo-controlled, double-blind, phase 3b trial demonstrated the superiority of secukinumab compared with placebo after 12 weeks of treatment (Bagel et al., 2017) .
A large proportion of patients with severe scalp psoriasis presents with minimal chronic plaque psoriasis on the body and, hence, may not receive systemic therapy indicated for moderate-to-severe chronic plaque psoriasis. The adjunctive use of keratolytic and tar-based shampoos, along with topical therapy (steroids and vitamin D analogs), may suffice initially, but long-term compliance can be poor. Localized ultraviolet B therapy using fiber-optic hair brushes is successful for patients, but these devices are expensive and patients need high allowances on their durable medical equipment insurance to obtain them. Use of methotrexate and biologics is much needed in these patients. However, approval through payers can prove difficult as current on-label indications require significant body-surface-area coverage or a high-enough PASI score to qualify for these systemic agents.
| Facial
Facial psoriasis typically presents at a younger age and is estimated to affect nearly 50% of patients with psoriasis (Canpolat et al., 2008) .
Further, the presence of highly visible lesions can result in considerable psychosocial problems (Beattie & Lewis-Jones, 2006) . The treatment of facial psoriasis is complicated by underappreciation of its prevalence despite being a marker of more severe disease (Canpolat et al., 2008) . In patients with facial psoriasis, whole-body PASI scores are typically higher (15.6) than in patients without facial involvement (6.9), and they are also more likely to have a Koebner phenomenon (70.2% vs. 29.8%) (Canpolat et al., 2008) . Additionally, psoriasis in this area is associated with longer disease duration, earlier onset, and frequently requires more extensive treatment, and it may sometimes be dismissed as seborrheic dermatitis or sebopsoriasis (Young Park, Hyun Rim, Beom Choe, & Il Youn, 2004).
Facial psoriasis is classified into 3 categories based on lesion distribution: mixed (39.1%), peripherofacial (37.1%), and centrofacial (23.7%) (van de Kerkhof et al., 2007) . Centrofacial involvement likely indicates patients with the most severe form of facial psoriasis because it is associated with higher mean total-body PASI scores, a lower age of onset, and requires more extensive treatment than the peripherofacial variant (Woo, Choi, Yoon, Jo, & Youn, 2008) . Patients with mixed type had significantly higher facial, scalp, and total-body PASI scores than the other 2 forms (Woo et al., 2008) . Patients with facial involvement are more likely to report nail involvement, pruritus, symptoms that worsen with trauma, and hospitalization due to psoriasis (Young Park et al., 2004) .
In recent years, research on facial psoriasis was limited to a small number of trials, and systemic therapy has been investigated in only a single study (Table 1) . For topical therapies, the immunomodulatory calcineurin inhibitor, tacrolimus, was more effective than calcitriol, whereas calcipotriol combined with hydrocortisone showed greater clearance than calcipotriol alone (Liao, Chiu, Tseng, & Tsai, 2007; Ortonne, Noerrelund, et al., 2010) . Topical pimecrolimus is also effective in treating facial psoriasis (Jacobi, Braeutigam, Mahler, Schultz, & Hertl, 2008) . In 1 post hoc analysis, systemic therapy with adalimumab was more efficacious than methotrexate and placebo (Navarini, Poulin, Menter, Gu, & Teixeira, 2014) .
In the short term, treatment can consist of milder topical steroids, but these agents present the risk of provoking acne, atrophy, and ocular side effects. Topical vitamin D analogs and pimecrolimus are effective steroid-sparing agents. For milder disease on the seborrheic dermatitis spectrum, ketoconazole 2% cream may be helpful.
| Intertriginous (inverse)
Inverse psoriasis typically presents as smooth, well-demarcated, inflamed areas, with little-to-no scaling and possible superficial erosion and maceration. These lesions result in intense itching, irritation from sweating, and soreness. Traditionally, inverse psoriasis was thought to be uncommon, but recent findings place the prevalence at 21-30% of patients with psoriasis (Merola, Li, et al., 2016) . For patients with inverse psoriasis, the groin is the most commonly affected area and the external genitalia are involved in almost 80% of patients (Wang, Li, Gao, & Liu, 2005) .
Treatment of inverse psoriasis must be approached with special care due to increased percutaneous absorption of steroids, phenols, and alcohols in the affected areas (Wozel, 2008) . Thus, ideal treatment options should be odorless, cosmetically acceptable, chemically and physically stable, not irritating, and have no systemic absorption (Wozel, 2008) . A review of treatment options for inverse psoriasis indicated that data were limited by a lack of clinical trials and the poor quality of published studies (Kalb et al., 2009) . With the evidence available, low-to mid-potency topical steroids were identified as first-line options for short-term treatment and calcipotriol or pimecrolimus/ tacrolimus for long-term therapy. However, calcipotriol can be irritating when used in skin folds (Kalb et al., 2009) . QoL data focused on patients with inverse disease are limited, but it likely represents a substantial burden in interpersonal interactions (Cohen et al., 2016) .
Severe inverse psoriasis resistant to topical treatment could necessitate the use of traditional oral systemic therapies, newer biologic therapies, or the phosphodiesterase 4 (PDE4) inhibitor, apremilast.
Additionally, targeted excimer laser therapy can be used for patients with psoriasis in defined focal areas.
| Genital
Genital psoriasis is found in about 30-40% of patients with psoriasis and is more common in men (Meeuwis et al., 2010; . Additionally, 63% of patients with psoriasis report ever having experienced genital psoriasis (Ryan et al., 2015) . Not all cases of genital psoriasis fall under the inverse category, with some cases demonstrating plaque disease.
Over two-thirds of patients with genital psoriasis have never applied treatment to their genital lesions (Meeuwis, van de Kerkhof, Massuger, de Hullu, & van Rossum, 2012) . Such undertreatment is likely due, at least in part, to patients not receiving options for managing the condition because 45% of patients who discussed genital lesions with their physician reported not receiving treatment (Meeuwis, de Hullu, van de Nieuwenhof et al., 2011) . Genital psoriasis has a significant negative effect on QoL and sexual health (Meeuwis, de Hullu, van de Nieuwenhof et al., 2011; Ryan et al., 2015) .
In a systematic literature review, only 7 studies on the treatment of genital psoriasis were identified, and these primarily consisted of case reports . Based on these limited results, low-potency topical corticosteroids were identified as first-line therapy followed by vitamin D preparations or tarbased treatments. Pimecrolimus cream may be beneficial when used to treat the glans penis. Additionally, topical tacrolimus, another immunomodulator, has been identified as a treatment option for males with genital psoriasis (Bissonnette, Nigen, & Bolduc, 2008) . Currently, a trial MEROLA ET AL. | 9 of 15 to determine the efficacy of ixekizumab toward genital psoriasis is ongoing (ClinicalTrials.gov NCT02718898).
In clinical practice, intermittent flares of genital psoriasis are treated with low-potency topical steroids, vitamin D analogs, calcineurin inhibitors, retinoids, or retinoid analogs (e.g., tazarotene). As with inverse psoriasis, severe cases of genital psoriasis can be treated with traditional systemic therapies, newer biologic therapies, or apremilast; however, specific data are lacking for the efficacy of biologic and small-molecule inhibitors in genital psoriasis.
| Hands and feet (palmoplantar)
Palmoplantar psoriasis occurs in 12-16% of patients with psoriasis (Merola, Li, et al., 2016) . The morphology can vary from predominately pustular lesions to thick hyperkeratotic plaques (Farley, Masrour, McKey, & Menter, 2009 ). Other dermatoses such as palmoplantar pustulosis and dermatitis repens (also known as acrodermatitis continua of Hallopeau) are generally included in the spectrum of disorders classified as palmoplantar psoriasis (Brunasso et al., 2013; Farley et al., 2009) .
Although involvement of the palms and soles often affects < 5% of total body surface area (and, consequently, may be characterized as mild disease when measured by PASI score), these patients may suffer from greater physical limitations than individuals with psoriasis in other areas (Farley et al., 2009; Pettey, Balkrishnan, Rapp, Fleischer, & Feldman, 2003) . Patients with palmoplantar psoriasis reported greater functional disability, burning, soreness, and health-related QoL impairment than patients with other forms of psoriasis, with 34% of patients being severely affected by their condition, 48% being moderately affected, and only 18% being mildly affected (Chung et al., 2014; Farley et al., 2009; Pettey et al., 2003) .
Treatment goals for palmoplantar psoriasis may differ from other forms of the disease, as considerable treatment satisfaction can be obtained by alleviating pain and discomfort (Pettey et al., 2003) .
Methotrexate significantly improved modified palmoplantar psoriasis area and severity index (m-PPPASI) scores relative to the retinoid acitretin (Table 1) (Janagond, Kanwar, & Handa, 2013) . Additionally, ustekinumab, secukinumab, and apremilast significantly improved palmoplantar psoriasis compared with placebo; and ixekizumab provided significant improvement compared to etanercept and placebo (Au et al., 2013; Bissonnette et al., 2016; Gottlieb et al., 2017; Menter et al., 2017; Paul et al., 2014) . However, infliximab failed to meet a primary endpoint of m-PPPASI 75 at week 14 compared with placebo (Bissonnette et al., 2011) .
The strategy for treatment of palmoplantar psoriasis varies based on the presence of pustular psoriasis. In the absence of pustular psoriasis, potent topical steroids, hand and foot ultraviolet therapy, bath psoralen plus ultraviolet A, tar-based soaps (liquor carbonis detergens), and compounded products (e.g., keratolytic with a potent steroid) are all considered effective treatment options. Vitamin D analogs may be prescribed, but are less effective in thick-skinned areas such as the hands and feet. More severe cases of palmoplantar psoriasis may require traditional systemic treatments such as methotrexate or acitretin, or newer biologic therapies such as secukinumab. The PDE4 inhibitor, apremilast is also efficacious toward palmoplantar psoriasis (Bissonnette et al., 2016) . In addition to these treatment options, recalcitrant cases of pustular palmoplantar psoriasis can be treated with oral or topical dapsone (Sheu, Divito, Enamandram, & Merola, 2016) .
| Nail
Nail involvement is found in 23-27% of patients with psoriasis (Merola, Li, et al., 2016) . The most common symptoms are pitting and onycholysis with subungual hyperkeratosis, nail-bed discoloration, nail-plate abnormalities, and, less frequently, splinter hemorrhages (Baran, 2010) .
Nail psoriasis is associated with significant pain and physical impairment (including from psoriatic arthritis, which may be more common with nail involvement), as well as issues such as: self-image and cosmetic concerns, difficulty with tasks involving manual dexterity, anxiety and/or depression, an increased number of missed work days relative to patients without nail involvement, and substantial impairments in QoL (Augustin et al., 2010; Klaassen, van de Kerkhof, & Pasch, 2014; Langley, Saurat, Reich, & Nail Psoriasis Delphi Expert Panel, 2012; Ortonne, Baran, et al., 2010) .
A systematic review evaluating treatments for nails psoriasis found the quality of published studies was generally poor (de Vries et al., 2013) . However, the anti-tumor necrosis factor monoclonal antibodies infliximab and golimumab, superficial radiotherapy, Grenz rays, and electron beam therapy were effective in comparative placebo-controlled studies. Systemic therapies were recommended only for individuals who required them for other psoriatic conditions, had severe nail psoriasis, were recalcitrant to other therapy, or had reduced QoL (de Vries et al., 2013) . Another option for nail psoriasis is intralesional steroidinjection therapy, which is limited by the pain of injection; however, recent data from a small (N 5 17) prospective trial suggested high efficacy for novel administration via needle-free jet injector (Nantel-Battista, Richer, Marcil, & Benohanian, 2014) . Laser therapy can also be considered for patients with nail psoriasis and in a single blinded left-toright comparison study (N 5 42), treatment with pulsed-dye laser was significantly more effective than excimer laser (Al-Mutairi, Noor, & Al-Haddad, 2014 (Langley et al., 2015; Merola, Tatulych, et al., 2016; Ortonne et al., 2013; Paul et al., 2012 Paul et al., , 2014 Rich et al., 2014 Rich et al., , 2016 Thaci et al., 2015; van de Kerkhof et al., 2017) . Results suggest that these patients could benefit from new agents that produce high levels of clearance in shorter periods. In 2015, the National Psoriasis Foundation issued the following best practice recommendations for the treatment of nail psoriasis (Crowley, Weinberg, Wu, Robertson, & Van Voorhees, 2015) . For patients with psoriasis limited to the nails, high-potency topical corticosteroids alone or in combination with calcipotriol were highly recommended, and intralesional corticosteroids can be considered. For patients with psoriasis limited to the nails who had failed topical therapy, the following therapies were recommended in order of preference: adalimumab, etanercept, intralesional corticosteroids, ustekinumab, methotrexate, and acitretin (Crowley et al., 2015) . Although biologics are the most effective option for nail psoriasis, their price can limit their use (Demirsoy et al., 2013) .
Nail psoriasis can be challenging to treat. Frequently, patients will first be treated with topical steroids, but this is often not sufficient.
Intralesional corticosteroids are effective, but painful. Radiotherapy, although not frequently employed, can be used for nonresponsive nails.
In cases of severe nail psoriasis, systemic treatments-of which biologics are most effective-can be used. (Patel, Liu, Qureshi, & Merola, 2014) .
| DI SCUS SION
Patient concerns and therapy limitations cause many commonly used agents to not be acceptable for treatment of psoriasis affecting the scalp, face, flexural/intertriginous, and palmoplantar regions ( Table 2 ). The application of topical agents can be challenging and not cosmetically tolerable to many patients. Further, traditional systemic therapies may require different drug concentrations to be effective at the afflicted areas; thus, toxicity can be a major concern. Also, treatment may be further complicated by lack of response due to nonadherence because of difficulty in maintaining application schedules or other reasons. In addition, treatment selection is hampered by a lack of robust clinical trial data for psoriasis in these areas (Table 1) . To determine the best treatment strategies, future trials may consider including individuals with psoriasis only in challenging-to-treat areas and incorporate QoL measures.
Recent advances in systemic treatments may benefit patients for whom topical approaches pose challenges. Through a more targeted approach directed at the underlying pathophysiology of lesion formation, new agents may offer greater efficacy in managing psoriasis of the head, flexures, and extremities, especially compared with traditional systemic agents that have limited distribution to certain areas. The development of biologic agents that target cytokines downstream of tumor necrosis factor-a could produce more rapid and more complete clearing of psoriatic lesions than current therapies. The implication of IL-17 in the pathogenesis of psoriasis has led to the development of new therapeutics aimed at IL-17 blockade, and these agents (e.g., secukinumab, ixekizumab) have strong efficacy and good safety in latephase clinical trials for moderate-to-severe plaque psoriasis Leonardi et al., 2012; Martin et al., 2013; Papp et al., 2012) . Additionally, the expression of IL-17A is increased in the palms and soles of patients with palmoplantar pustular psoriasis, and targeting of IL-17A with secukinumab is efficacious in patients with moderateto-severe palmoplantar psoriasis (Bissonnette et al., 2014; Gottlieb et al., 2017) . In contrast, targeting IL-12/23 has limited efficacy in palmoplantar psoriasis (Bissonnette et al., 2014) . Secukinumab also significantly improved moderate-to-severe scalp psoriasis in a prospective phase 3b trial (Bagel et al., 2017) . Results are awaited from a prospective phase 3 trial of secukinumab in nail psoriasis (ClinicalTrials.gov NCT01807520; ClinicalTrials.gov NCT02267135).
Although additional data are necessary to determine the role of agents targeting IL-17 for routine management of psoriasis in other areas and nonplaque subsets, they may offer improved care and outcomes for patients whose needs are not met by available therapies. Raising the awareness of psoriasis on the scalp, face, intertriginous areas, genitals, hands, feet, and nails is critical for comprehensive assessment of psoriasis. Currently, more targeted systemic therapies are available for psoriasis than in the past, and use of drugs discussed in this manuscript is important for improving clinical outcomes of all patients, regardless of affected body region. We recommend addressing the current gap in comprehensive psoriasis management through the development of better measurement tools that include all psoriasis phenotypes and incorporate the patient perspective as patientreported outcomes, so that clinical trials can be conducted using these new psoriasis indices.
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